These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36449471)

  • 1. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
    Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
    [No Abstract]   [Full Text] [Related]  

  • 2. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.
    Jackson R; Brams MN; Citrome L; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    Neuropsychiatr Dis Treat; 2021; 17():1589-1597. PubMed ID: 34079257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.
    Trosch RM; Comella CL; Caroff SN; Ondo WG; Shillington AC; LaChappelle BJ; Hauser RA; Correll CU; Friedman JH
    J Clin Psychiatry; 2024 Jan; 85(1):. PubMed ID: 38270545
    [No Abstract]   [Full Text] [Related]  

  • 5. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.
    Caroff SN; Citrome L; Meyer J; Sajatovic M; Goldberg JF; Jain R; Lundt L; Lindenmayer JP; McEvoy JP; McIntyre RS; Tohen M; Ketter TA
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
    Tanner CM; Caroff SN; Cutler AJ; Lenderking WR; Shalhoub H; Pagé V; Franey EG; Serbin M; Yonan C
    J Patient Rep Outcomes; 2023 Mar; 7(1):21. PubMed ID: 36892733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop.
    Kane JM; Correll CU; Nierenberg AA; Caroff SN; Sajatovic M;
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29742330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37022752
    [No Abstract]   [Full Text] [Related]  

  • 10. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
    Caroff SN; Yeomans K; Lenderking WR; Cutler AJ; Tanner CM; Shalhoub H; Pagé V; Chen J; Franey E; Yonan C
    J Clin Psychopharmacol; 2020; 40(3):259-268. PubMed ID: 32332461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.
    Rekhi G; Tay J; Lee J
    J Psychopharmacol; 2022 Feb; 36(2):183-190. PubMed ID: 34979813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Patient Rep Outcomes; 2023 Nov; 7(1):122. PubMed ID: 38015301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel.
    El-Mallakh RS; Belnap A; Iyer S; Schreiber J; Matthews D; Lefler L; Dees D; Bott A; Vanegas-Arroyave N; Wolff A; Pesce U; Farahmand K; Shah C; Lundt L
    Telemed J E Health; 2023 Jul; 29(7):1096-1104. PubMed ID: 36520584
    [No Abstract]   [Full Text] [Related]  

  • 14. Earlier Diagnosis of Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31846242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia.
    Dilks S; Xavier RM; Kelly C; Johnson J
    Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia: motor system impairments, cognition and everyday functioning.
    Strassnig M; Rosenfeld A; Harvey PD
    CNS Spectr; 2018 Dec; 23(6):370-377. PubMed ID: 28877766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders.
    Caroff SN; Leong SH; Roberts C; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(1):38-45. PubMed ID: 31834084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
    Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.
    Barer Y; Ribalov R; Yaari A; Maor R; Arow Q; Logan J; Chodick G; Arkadir D; Eitan R
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):454-460. PubMed ID: 36018237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.